Venture&Growth
Venture&Growth
All Portfolio items
See full Venture&Growth portfolio
Innate Pharma is a biopharmaceutical company developing first-in-class immunotherapy drugs for cancer and inflammatory diseases. These novel drugs consist of monoclonal antibodies that can activate the innate immune system.
Backed by Gilde as an investor, Innate Pharma has advanced its product pipeline to the clinical development stage and built strong commercial partnerships with Novo Nordisk and Bristol-Myers Squibb.
Innate Pharma operates from Marseille, France, and was successfully listed at Euronext Paris (IPH) after its IPO in 2006.
More Innate Pharma news
Innate Pharma signs Global License Agreement with BMS, potential deal value up to $465 million
INNATE PHARMA initiates collaboration with Celgene
Innate Pharma reports positive phase IIa in type C viral hepatitis
INNATE PHARMA Swaps Products with NOVO NORDISK A/S to Obtain full Commercial Rights
Venture&Growth
Mobia Medical
Mobia Medical is a U.S.-based, growth-stage company commercializing the Vivistim Paired VNS System, an implantable neurostimulation therapy that improves outcomes for chronic ischemic stroke survivors with upper limb motor deficits. Vivistim Paired VNS System is an implantable neurostimulation therapy that
Venture&Growth
Nalu Medical
Nalu Medical is a US medical device company that commercializes alternative proprietary neuromodulation systems. These systems treat chronic neuropathic pain in the back, legs, and other peripheral parts of the body, affecting 1.5 million patients. Nalu’s miniaturized implantable pulse generator
Venture&Growth
CatalYm
CatalYm is a clinical-stage immuno-oncology company improving the outcomes of existing checkpoint inhibitor therapies in difficult-to-treat cancer types. The company has identified GDF-15 as a key cancer therapy resistance mechanism and is developing it as a safe and efficacious immune
